Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2010, Article ID 453851, 6 pages
http://dx.doi.org/10.4061/2010/453851
Review Article

Research Needed to Support Clinical Use of Biomarkers as Prognostic Indicators for Patients with Heart Failure

1Center for Chronic Disease Outcomes Research, VA Medical Center, One Veterans Drive, Minneapolis, MN 55417, USA
2Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
3Department of Cardiology, VA Medical Center, One Veterans Drive, Minneapolis, MN 55417, USA

Received 19 March 2010; Accepted 28 April 2010

Academic Editor: Hector Ventura

Copyright © 2010 Thomas S. Rector and Inder S. Anand. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. R. B. de Virginy, “Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure: a clinical review,” Heart Failure Reviews, vol. 11, no. 4, pp. 333–334, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. D. S. Lee and R. S. Vasan, “Novel markers for heart failure diagnosis and prognosis,” Current Opinion in Cardiology, vol. 20, no. 3, pp. 201–210, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Jourdain, G. Jondeau, F. Funck et al., “Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP ulticenter Study,” Journal of the American College of Cardiology, vol. 49, no. 16, pp. 1733–1739, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Pfisterer, P. Buser, H. Rickli et al., “BNP-guided vs symptom-guided heart failure therapy the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial,” Journal of the American Medical Association, vol. 301, no. 4, pp. 383–392, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Jessup, W. T. Abraham, D. E. Casey et al., “2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation,” Circulation, vol. 119, no. 14, pp. 1977–2016, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Cheng, R. Kazanagra, A. Garcia et al., “A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study,” Journal of the American College of Cardiology, vol. 37, no. 2, pp. 386–391, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Bettencourt, A. Azevedo, J. Pimenta, F. Friões, S. Ferreira, and A. Ferreira, “N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients,” Circulation, vol. 110, no. 15, pp. 2168–2174, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. W. C. Levy, K. L. Lee, A. S. Hellkamp et al., “Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population,” Circulation, vol. 120, no. 10, pp. 835–842, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Hlatky, P. Greenland, D. K. Arnett et al., “On behalf of the American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk; a scientific statement from the American Heart Association,” Circulation, vol. 119, pp. 2408–2416, 2009. View at Google Scholar
  10. S. M. Dunlay, Y. Gerber, S. A. Weston, J. M. Killian, M. M. Redfield, and V. L. Roger, “Prognostic value of biomarkers in heart failure: application of novel methods in the community,” Circulation: Heart Failure, vol. 2, no. 5, pp. 393–400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Lemeshow, J. Klar, and D. Teres, “Outcome prediction for individual intensive care patients: useful, misused, or abused?” Intensive Care Medicine, vol. 21, no. 9, pp. 770–776, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Henderson and N. Keiding, “Individual survival time prediction using statistical models,” Journal of Medical Ethics, vol. 31, no. 12, pp. 703–706, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. A. J. Vickers, B. S. Kramer, and S. G. Baker, “Selecting patients for randomized trials: a systematic approach based on risk group,” Trials, vol. 7, no. 30, pp. 1–8, 2006. View at Google Scholar
  14. J. N. Cohn and G. Tognoni, “A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure,” The New England Journal of Medicine, vol. 345, no. 23, pp. 1667–1675, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. I. S. Anand, L. D. Fisher, Y.-T. Chiang et al., “Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT),” Circulation, vol. 107, no. 9, pp. 1278–1283, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Latini, S. Masson, I. S. Anand et al., “Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure,” Circulation, vol. 116, no. 11, pp. 1242–1249, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. S. Pepe, H. Janes, G. Longton, W. Leisenring, and P. Newcomb, “Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker,” American Journal of Epidemiology, vol. 159, no. 9, pp. 882–890, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Leisenring, T. Alonzo, and M. S. Pepe, “Comparisons of predictive values of binary medical diagnostic tests for paired designs,” Biometrics, vol. 56, no. 2, pp. 345–351, 2000. View at Google Scholar · View at Scopus
  19. S. Greenland, “The need for reorientation toward cost-effective prediction: comments on ‘Evaluating the added predictive of a new marker: from area under the ROC curve to reclassification and beyond’,” Statistics in Medicine, vol. 27, no. 2, pp. 199–206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. N. R. Cook and P. M. Ridker, “Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures,” Annals of Internal Medicine, vol. 150, no. 11, pp. 795–802, 2009. View at Google Scholar · View at Scopus
  21. H. Janes, M. S. Pepe, and W. Gu, “Assessing the value of risk predictions by using risk stratification tables,” Annals of Internal Medicine, vol. 149, no. 10, pp. 751–760, 2008. View at Google Scholar · View at Scopus
  22. J. G. Pigeon and J. F. Heyse, “An improved goodness of fit statistic for probability prediction models,” Biometrical Journal, vol. 41, no. 1, pp. 71–82, 1999. View at Google Scholar · View at Scopus
  23. M. J. Pencina, R. B. D'Agostino Sr., R. B. D'Agostino Jr., and R. S. Vasan, “Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond,” Statistics in Medicine, vol. 27, no. 2, pp. 157–172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. O. Melander, C. Newton-Cheh, P. Almgren et al., “Novel and conventional biomarkers for prediction of incident cardiovascular events in the community,” Journal of the American Medical Association, vol. 302, no. 1, pp. 49–57, 2009. View at Publisher · View at Google Scholar · View at Scopus